Lack of effect of growth hormone replacement therapy on CYP1A2 and xanthine oxidase activities in growth hormone-deficient children

European Journal of Clinical Pharmacology

Volumn 62, Issue 2, 2006, Pages 123-127

  Mayayo Sinués, Esteban ^a   Fanlo, Ana ^a   Sinués, Bianca ^a   Mayayo, Esteban ^b   Labarta, Jose I ^b   García De Jalón, Angel ^b   Ferrández Longás, Angel ^b  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Children; CYP1A2; GH deficiency; rhGH therapy; Xanthine oxidase

Indexed keywords

1 METHYLURIC ACID; 1 METHYLXANTHINE; 1,7 DIMETHYLURIC ACID; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; CAFFEINE; CYTOCHROME P450 1A2; RECOMBINANT GROWTH HORMONE; XANTHINE OXIDASE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GROWTH HORMONE DEFICIENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE SUBSTITUTION; HUMAN; MALE; METABOLITE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; URINE LEVEL;

ADOLESCENT; BIOLOGICAL MARKERS; CAFFEINE; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP1A2; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; MALE; RECOMBINANT PROTEINS; XANTHINE OXIDASE;

EID: 33645399734     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0082-y     Document Type: Article

References (36)

1. Roehr B (2003) The many faces of human growth hormone. BETA 15:12-16
2. Thummel KE, Schenkman JB (1990) Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. Mol Pharmacol 37:119-129
3. Bienvenu T, Pons G, Rey E, Richard MO, d'Athis P, Arnaud MJ et al (1990) Effect of growth hormone on caffeine metabolism in hypophysectomized rats. Drug Metab Dispos 18:327-330
4. Grgurevich S, Greene FE (1995) Selective suppression of glutathione S-transferase activities in rat primary hepatocytes by growth hormone. Pharmacology 51:13-23
5. Flores-Morales A, Stahlberg N, Tollet-Egnell P, Lundeberg J, Malek RL, Quackenbush J et al (2001) Microarray analysis of the in vivo effects of hypophysectomy and growth hormone treatment on gene expression in the rat. Endocrinology 142:3163-3176
6. Gonzalez F, Liu S, Yano M (1993) Regulation of cytochrome P450 genes: molecular mechanisms. Pharmacogenetics 3:51-57
7. Waxman DJ, Ram PA, Park SH, Choi HK (1995) Intermittent plasma growth hormone triggers tyrosine phosphorylation and nuclear translocation of a liver-expressed, Stat5-related ADN binding protein. Proposed role as an intracellular regulator of male-specific liver gene transcription. J Biol Chem 270:13262-13270
8. Redmond GP, Bell JJ, Perel JM (1978) Effect of human growth hormone on amobarbital metabolism in children. Clin Pharmacol Ther 24:213-218
9. Redmond G, Bell JJ, Nichola PS, Perel JM (1980) Effect of growth hormone on human drug metabolism: time course and substrate specificity. Pediatr Pharmacol 1:63-70
10. Levitsky LL, Schoeller DA, Lambert GH, Edidin DV (1989) Effect of growth hormone therapy in growth hormone-deficient children on cytochrome P-450-dependent 3-N-demethylation of caffeine as measured by the caffeine 13CO2 breath test. Dev Pharmacol Ther 12:90-95
11. Gil-Berglund E, Johannsson G, Beck O, Bengtsson BA, Rane A (2002) Growth hormone replacement therapy induces codeine clearance. Eur J Clin Invest 32:507-512
12. Sinués B, Mayayo E, Fanlo A, Mayayo E Jr, Bernal ML, Bocos P et al (2004) Effects of growth hormone deficiency and rhGH replacement therapy on the 6β-hydroxycortisol/free cortisol ratio, a marker of CYP3A activity, in growth hormone-deficient children. Eur J Clin Pharmacol 60:559-564
13. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB et al (1992) Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2:116-127
14. Campbell ME, Spielberg SP, Kalow WA (1987) A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 42:157-165
15. Grant DM, Tang BK, Campbell ME, Kalow W (1986) Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol 21:454-458
16. Sinues B, Saenz MA, Lanuza J, Bernal ML, Fanlo A, Juste JL et al (1999) Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Cancer Epidemiol Biomarkers Prev 8:159-166
17. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP et al (1993) Major pathway of imipramine metabolism is catalyzed by cytochromes P4501A2 and P4503A4 in human liver. Mol Pharmacol 43:827-832
18. Nielsen KK, Brösen K, Hansen MG, Gram LF (1994) Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 55:518-527
19. Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U et al (1994) Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38:471-473
20. Carrillo JA, Dahl ML, Svensson JO, Aim C, Rodriguez I, Bertilsson L (1996) Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 60:183-190
21. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ et al (1996) Identification of the human cytochromes P450 responsible for the in vitro formation of major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 276:658-666
22. Madden S, Woolf TF, Pool WF, Park BK (1993) An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol 46:13-20
23. Arlander E, Ekstrom G, Aim C, Carrillo JA, Bielenstein M, Bottiger Y et al (1998) Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther 64:484-491
24. Shimada T, Iwasaki M, Martin MV, Guengerich FP (1989) Human liver microsomal cytochrome P450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/pSK 1002. Cancer Res 49:3218-3228
25. Kitada M, Taneda M, Ohta K, Nagashima K, Itahaski K, Kamataki T (1990) Metabolic activation of aflatoxin B1 and 2-amino-3-methylimidazo[4,5-f]- quinoline by human adult and fetal livers. Cancer Res 50:2641-2645
26. Gallagher EP, Wienkers LC, Stapleton PL, Kunze K, Eaton DL (1994) Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Res 54:101-108
27. Pritsos CA (2000) Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem Biol Interact 129:195-208
28. Pan SS, Bachur NR (1980) Xanthine oxidase catalyzed reductive cleavage of anthracycline antibiotics and free radical formation. Mol Pharmacol 17:95-99
29. Dodion P, Bernstein AL, Fox BM, Bachur NR (1987) Loss of fluorescence by anthracycline antibiotics: effects of xanthine oxidase and identification of the nonfluorescent metabolites. Cancer Res 47:1036-1039
30. Southorn PA, Powis G (1988) Free radicals in medicine. II. Involvement in human disease. Mayo Clin Proc 63:390-408
31. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W (1991) Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 49:648-657
32. Kalow W, Tang BK (1991) Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 50:508-519
33. Center for Drug Evaluation and Research (2000) Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products: general considerations. Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD
34. Tang BK, Zhou Y, Kadar D, Kalow W (1994) Caffeine as a probe for CYP1A2 activity: potential of renal factors on urinary phenotypic trait measurement. Pharmacogenetics 4:117-124
35. Sinues B, Fanlo A, Bernal ML, Mayayo E, Soriano MA, Martínez- Ballarín E (2002) Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity. Ther Drug Monit 24:715-721
36. Bozikas VP, Papakosta M, Niopas I, Karavatos A, Mirtsou-Fidani V (2004) Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. Eur Neuropsychopharmacol 14:39-44